LakeShore Biopharma Co., Ltd (LSBCF) - Cash Flow Conversion Efficiency
Based on the latest financial reports, LakeShore Biopharma Co., Ltd (LSBCF) has a cash flow conversion efficiency ratio of -0.001x as of June 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-693.96K) by net assets ($1.27 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See LakeShore Biopharma Co., Ltd (LSBCF) net asset quality to measure how much of total assets are equity-financed.
LakeShore Biopharma Co., Ltd - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how LakeShore Biopharma Co., Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check LSBCF cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
LakeShore Biopharma Co., Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of LakeShore Biopharma Co., Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
International Prospect Ventures Ltd
V:IZZ
|
-0.357x |
|
EVERYBODY LOVES LANGUAGES
F:VB6
|
N/A |
|
Powell Max Limited Class A Ordinary Shares
NASDAQ:PMAX
|
0.544x |
|
Lyc Healthcare Bhd
KLSE:0075
|
2.300x |
|
Mobeus Income And Growth Vct Plc
LSE:MIX
|
-0.004x |
|
Fintech Chain Ltd
AU:FTC
|
-0.019x |
|
ProAm Explorations Corp
V:PMX
|
0.370x |
|
Tlou Energy Ltd
AU:TOU
|
-1.918x |
Annual Cash Flow Conversion Efficiency for LakeShore Biopharma Co., Ltd (2021–2025)
The table below shows the annual cash flow conversion efficiency of LakeShore Biopharma Co., Ltd from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see LakeShore Biopharma Co., Ltd (LSBCF) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $499.75 Million | $-120.98 Million | -0.242x | +52.01% |
| 2024-03-31 | $585.21 Million | $-295.23 Million | -0.504x | -101.40% |
| 2023-03-31 | $728.45 Million | $-182.47 Million | -0.250x | +73.92% |
| 2022-03-31 | $180.68 Million | $-173.55 Million | -0.961x | +99.99% |
| 2021-03-31 | $21.36K | $-246.61 Million | -11543.271x | -- |
About LakeShore Biopharma Co., Ltd
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, discovers, develops, manufactures, commercializes, and sells vaccines and therapeutic biologics for infectious diseases and cancer. Its product pipeline includes YSJA, a conventional rabies vaccine, which is in marketed stage; PIKA, a rabies vaccine, which is in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS… Read more